Vor Biopharma (NASDAQ:VOR) Upgraded by Robert W. Baird to "Outperform" Rating

Key Points

• Vor Biopharma has been upgraded from a "neutral" to an "outperform" rating by Robert W. Baird, with the price target increased from $20.00 to **$64.00**, indicating a potential upside of **107.72%**.
• The company recently reported a **Q2 earnings loss of $43.60** per share, significantly missing analysts' expectations of a loss of $11.40.
• Despite the upgrades, the stock has seen trading down **4.6%** and has a twelve-month high of **$65.80** and a low of **$2.62**.

Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by equities researchers at Robert W. Baird from a "neutral" rating to an "outperform" rating in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage presently has a $64.00 price objective on the stock, up from their prior price objective of $20.00. Robert W. Baird's target price would suggest a potential upside of 107.72% from the stock's current price.

Other research analysts have also recently issued reports about the company. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Stifel Nicolaus raised Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective for the company in a research report on Wednesday, September 24th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Vor Biopharma in a research report on Thursday, August 14th. Wall Street Zen cut Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Finally, Zacks Research cut Vor Biopharma from a "hold" rating to a "strong sell" rating in a report on Monday. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $77.83.

Vor Biopharma Trading Down 4.6%

VOR stock opened at $30.81 on Wednesday. The company has a market capitalization of $211.05 million, a P/E ratio of -0.11 and a beta of 2.07. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80. The business's fifty day moving average price is $37.28.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Insider Activity

In other news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the business's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total value of $688,808.12. Following the transaction, the insider directly owned 32,781,209 shares of the company's stock, valued at $50,483,061.86. The trade was a 1.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 1,021,203 shares of company stock valued at $21,890,146. 0.45% of the stock is owned by insiders.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently modified their holdings of VOR. Jane Street Group LLC bought a new position in Vor Biopharma during the first quarter valued at $140,000. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma during the first quarter valued at about $100,000. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd bought a new stake in Vor Biopharma during the 2nd quarter valued at approximately $66,000. Finally, Money Concepts Capital Corp boosted its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.